Lifecore Biomedical (LFCR) Competitors $6.74 -0.02 (-0.22%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LFCR vs. XFOR, ELVN, COLL, PHVS, SYRE, MLYS, NTLA, NRIX, GYRE, and RCUSShould you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include X4 Pharmaceuticals (XFOR), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Pharvaris (PHVS), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Lifecore Biomedical vs. X4 Pharmaceuticals Enliven Therapeutics Collegium Pharmaceutical Pharvaris Spyre Therapeutics Mineralys Therapeutics Intellia Therapeutics Nurix Therapeutics Gyre Therapeutics Arcus Biosciences X4 Pharmaceuticals (NASDAQ:XFOR) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Does the MarketBeat Community believe in XFOR or LFCR? X4 Pharmaceuticals received 76 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 68.10% of users gave X4 Pharmaceuticals an outperform vote while only 25.00% of users gave Lifecore Biomedical an outperform vote. CompanyUnderperformOutperformX4 PharmaceuticalsOutperform Votes7968.10% Underperform Votes3731.90% Lifecore BiomedicalOutperform Votes325.00% Underperform Votes975.00% Do institutionals & insiders have more ownership in XFOR or LFCR? 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 1.6% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 32.2% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is XFOR or LFCR more profitable? X4 Pharmaceuticals has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -12.52%. X4 Pharmaceuticals' return on equity of -236.19% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets X4 PharmaceuticalsN/A -236.19% -75.14% Lifecore Biomedical -12.52%-315.23%-12.74% Do analysts recommend XFOR or LFCR? X4 Pharmaceuticals currently has a consensus price target of $85.00, indicating a potential upside of 2,154.64%. Lifecore Biomedical has a consensus price target of $8.00, indicating a potential upside of 18.61%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor XFOR or LFCR? In the previous week, X4 Pharmaceuticals had 13 more articles in the media than Lifecore Biomedical. MarketBeat recorded 16 mentions for X4 Pharmaceuticals and 3 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.23 beat X4 Pharmaceuticals' score of -0.06 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, XFOR or LFCR? X4 Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Which has stronger valuation and earnings, XFOR or LFCR? Lifecore Biomedical has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 Pharmaceuticals$2.56M256.04-$101.17M-$0.19-19.84Lifecore Biomedical$130.86M1.91$12.01M-$1.45-4.65 SummaryX4 Pharmaceuticals beats Lifecore Biomedical on 10 of the 18 factors compared between the two stocks. Get Lifecore Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFCR vs. The Competition Export to ExcelMetricLifecore BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$250.29M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-12.077.4422.4418.48Price / Sales1.91242.70393.95103.59Price / CashN/A65.8538.1834.62Price / Book18.276.516.774.25Net Income$12.01M$143.21M$3.22B$248.23M7 Day Performance9.56%1.98%1.45%0.89%1 Month Performance-3.84%6.89%3.96%3.53%1 Year Performance4.97%-2.52%16.07%5.08% Lifecore Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFCRLifecore Biomedical1.6419 of 5 stars$6.75-0.2%$8.00+18.6%+5.3%$249.55M$130.86M-12.04690XFORX4 Pharmaceuticals3.8475 of 5 stars$5.34-6.3%$85.00+1,491.8%-87.2%$927.36M$2.56M-59.3380Stock SplitNews CoverageGap DownHigh Trading VolumeELVNEnliven Therapeutics2.2596 of 5 stars$18.91+3.8%$40.33+113.3%+8.9%$926.67MN/A-9.9550News CoveragePositive NewsGap DownCOLLCollegium Pharmaceutical4.044 of 5 stars$26.87+0.3%$43.60+62.3%-26.9%$904.19M$631.45M11.58210Upcoming EarningsPositive NewsPHVSPharvaris2.0173 of 5 stars$17.06+1.3%$42.67+150.1%-24.8%$892.07MN/A-6.0930Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeSYRESpyre Therapeutics1.9151 of 5 stars$14.67+3.8%$49.57+237.9%-53.9%$884.25M$890,000.00-1.96100Upcoming EarningsNews CoveragePositive NewsMLYSMineralys Therapeutics2.3863 of 5 stars$13.56+1.6%$33.00+143.4%+16.0%$879.72MN/A-3.7328Upcoming EarningsShort Interest ↑NTLAIntellia Therapeutics4.5482 of 5 stars$8.48+2.0%$36.68+332.6%-58.6%$877.82M$57.88M-1.56600Upcoming EarningsPositive NewsNRIXNurix Therapeutics1.9305 of 5 stars$11.47-0.8%$30.44+165.4%-4.1%$874.43M$56.42M-3.97300Analyst ForecastGYREGyre Therapeutics0.0667 of 5 stars$9.32+2.8%N/A-37.4%$873.69M$105.76M186.4040Upcoming EarningsNews CoverageRCUSArcus Biosciences2.2787 of 5 stars$8.25-0.6%$28.38+243.9%-42.6%$867.39M$258M-2.62500Upcoming EarningsPositive News Related Companies and Tools Related Companies X4 Pharmaceuticals Competitors Enliven Therapeutics Competitors Collegium Pharmaceutical Competitors Pharvaris Competitors Spyre Therapeutics Competitors Mineralys Therapeutics Competitors Intellia Therapeutics Competitors Nurix Therapeutics Competitors Gyre Therapeutics Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFCR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LFCR Stock Free LFCR Stock Alerts